Second-generation antipsychotics and bone turnover in schizophrenia

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 137-141

  Okita, Kyoji ^a   Kanahara, Nobuhisa ^a,b   Nishimura, Motoi ^a,c   Yoshida, Toshihiko ^c   Yasui Furukori, Norio ^d   Niitsu, Tomihisa ^a   Yoshida, Taisuke ^a   Ishikawa, Masatomo ^a   Kimura, Hiroshi ^a   Nomura, Fumio ^a,c   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Bone turnover; Osteoporosis; Schizophrenia; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ARIPIPRAZOLE; BLONANSERIN; ESTRADIOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; TESTOSTERONE; UNCLASSIFIED DRUG; ACID PHOSPHATASE; BIOLOGICAL MARKER; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SEX DIFFERENCE; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS;

ACID PHOSPHATASE; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; ESTRADIOL; FEMALE; HUMANS; HYPERPROLACTINEMIA; ISOENZYMES; MALE; PROLACTIN; SCHIZOPHRENIA; SEX FACTORS; TESTOSTERONE;

EID: 84904095590     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.009     Document Type: Article

References (29)

1. Abraham G., Paig W.W., Kaminski J., Joseph A., Kohegyi E., Josiasssen R.C. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am. J. Psychiatry 2003, 160:1618-1620.
2. Baastrup P.C., Christiansen C., Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980, 6:56-59.
3. Becker D., Liver O., Mester R., Rapoport M., Weizman A., Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J. Clin. Psychiatry 2003, 64:761-766.
4. Castro J.P., Joseph L.A., Shin J.J., et al. Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutr. Metab. 2005, 2:9.
5. Cawthon P.M. Gender differences in osteoporosis and fractures. Clin. Orthop. Relat. Res. 2011, 469:1900-1905.
6. Civitelli R., Armamento-Villareal R., Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos. Int. 2009, 20:843-851.
7. De Laet C.E., Pols H.A. Fractures in the elderly: epidemiology and demography. Baillieres Best Pract Res Clin Endocrinol Metab 2000, Harcourt Publishers, England.
8. Elefteriou F., Ahn J.D., Takeda S., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
9. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Miner. Res. 2000, 15:1526-1536.
10. Gullberg B., Johnell O., Kanis J.A. World-wide projections for hip fracture. Osteoporos. Int. 1997, 7:407-413.
11. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(Suppl. 1):53-67.
12. Halbreich U., Rojansky N., Palter S., et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 1995, 57:485-491.
13. Halleen J.M., Ylipahkala H., Alatalo S.L., et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif. Tissue Int. 2002, 71:20-25.
14. Hummer M., Malik P., Gasser R.W., et al. Osteoporosis in patients with schizophrenia. Am. J. Psychiatry 2005, 162:162-167.
15. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medication or risperidone. Psychoendocrinology 2003, 28:55-68.
16. Kishimoto T., Watanabe K., Shimada N., et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J. Clin. Psychiatry 2008, 69:385-391.
17. Kleinberg D.L., Davis J.M., de Coster R., van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999, 19:57-61.
18. Lane J.M., Serota A.C., Raphael B. Osteoporosis: differences and similarities in male and female patients. Orthop. Clin. N. Am. 2006, 37:601-609.
19. Lee T.Y., Chung M.Y., Chung H.K., Choi J.H., Kim T.Y., So H.S. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatr. Investig. 2010, 7:278-284.
20. Manolagas S.C., Kousteni S., Jilka R.L. Sex steroids and bone. Recent Prog. Horm. Res. 2002, 57:385-409.
21. Meaney A.M., O'Keane V.O. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr. Res. 2007, 93:136-143.
22. Molina P. Endocrine Physiology 2009, McGraw-Hill Education, Ohio. Third ed.
23. Nenonen A., Cheng S., Ivaska K., et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J. Bone Miner. Res. 2005, 20:1804-1812.
24. O'Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J. Clin. Psychopharmacol. 2005, 25:26-31.
25. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J. Psychopharmacol. 2008, 22(Suppl. 2):70-75.
26. Remes T., Väisänen S.B., Mahonen A., et al. The association of bone metabolism with bone mineral density, serum sex hormone concentrations, and regular exercise in middle-aged men. Bone 2004, 35:439-447.
27. Renn J.H., Yang N.P., Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet. Disord. 2010, 11:35.
28. Sugawara N., Yasui-Furukori N., Fujita A., et al. No association between bone mass and prolactin levels among patients with schizophrenia. Hum. Psychopharmacol. 2011, 26:596-601.
29. Yadav V.K., Oury F., Suda N., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.